|
Patent landscape, scope, and claims: |
Patent Analysis for U.S. Patent 4,626,531
What Does U.S. Patent 4,626,531 Cover?
U.S. Patent 4,626,531, issued on December 2, 1986, is titled "3-Hydroxypyridine Derivatives". It claims a class of chemical compounds defined by specific structural formulas designed for pharmaceutical applications. The patent also details methods for synthesizing these compounds and their potential use as pharmaceutical agents, notably as anti-inflammatory and analgesic agents.
Key Claims and Scope
The patent's scope primarily encompasses:
-
Chemical Scope: Derivatives of 3-hydroxypyridine with various substitutions on the aromatic ring and side chains. It lists explicit substituents, such as alkyl, alkoxy, halogen groups, among others.
-
Pharmacological Use: The compounds are claimed for their utility in treating inflammatory conditions, pain, and associated symptoms. The utility claims extend to pharmaceutical compositions comprising these compounds.
-
Synthesis Methods: The patent discloses processes for manufacturing these derivatives, including specific reaction steps, reagents, and conditions.
Claim Breakdown
Independent Claims (Claims 1, 10, 13)
-
Claim 1: Defines the basic chemical structure of the claimed derivatives, including specific substituents at defined positions on the pyridine ring.
-
Claim 10: Expands scope to include pharmaceutical compositions containing claimed derivatives with a pharmaceutically acceptable carrier.
-
Claim 13: Covers methods of treatment using the stated compounds.
Dependent Claims
-
Specify particular substituents, such as halogen groups (e.g., fluorine, chlorine), specific alkyl chains, and particular formulations (e.g., tablets, injections).
-
Add process limitations, for instance, specific reaction conditions like temperature ranges and reagents.
Patent Classification and Landscape
-
Classes: The patent falls under the U.S. Cooperative Patent Classification (CPC) system classes A61K31/435 (heterocyclic compounds with nitrogen atoms) and C07D (heterocyclic compounds containing nitrogen).
-
Related Patents: Numerous patents cite or relate to pyridine derivatives with similar structures aimed at pharmacological applications, especially in NSAID-like compounds and anti-inflammatory agents.
Patent Landscape for Pyridine Derivatives
Active Patent Sector
-
Study of patents filed from the 1980s to recent years reveals significant activity in the realm of heterocyclic compounds, particularly pyridine and its derivatives, for anti-inflammatory, analgesic, and CNS indications.
-
Major pharmaceutical companies (e.g., Pfizer, GSK, Novartis) have filed patents covering similar chemical scaffolds, reflecting ongoing interest.
Patent Expiration and Freedom-to-Operate
-
Patent 4,626,531 expired in December 2003, given its 17-year lifespan from issuance, opening the scope for research, development, and generic manufacturing.
-
Current patent landscape includes newer patents covering specific derivatives, formulations, or methods of use, limiting direct freedom-to-operate for similar compounds without licensing.
Key Patent Owners and Trends
-
The patent was assigned to Union Carbide Corporation, indicative of corporate R&D investments during the 1980s in heterocyclic compounds.
-
Recent trends highlight a shift toward derivatives with improved bioavailability, reduced toxicity, or targeted delivery systems, often protected by new patents.
Implications for R&D and Commercialization
-
The expired status of U.S. Patent 4,626,531 creates opportunities for development of generic or new derivative-based pharmaceuticals.
-
However, the existence of subsequent patents may restrict the scope of development to specific modifications or formulations.
-
Innovators should conduct thorough freedom-to-operate analyses when considering compounds structurally similar to those claimed.
Summary comparative table
| Aspect |
Details |
| Patent Number |
4,626,531 |
| Issue Date |
December 2, 1986 |
| Expiration Date |
December 2, 2003 |
| Main Claims |
3-hydroxypyridine derivatives for anti-inflammatory use |
| Chemical Class |
Heterocyclic pyridine derivatives |
| Key Claims included |
Structural formulas, synthesis methods, therapeutic methods |
| Patent Classification |
A61K31/435, C07D |
| Related Patents |
Multiple, focused on pyridine derivatives and NSAID-like compounds |
| Current Patent Status |
Expired, open for research and development |
Key Takeaways
-
U.S. Patent 4,626,531 provides broad claims on 3-hydroxypyridine derivatives with claimed anti-inflammatory and analgesic use, focusing on specific structural features.
-
The patent expired in 2003, allowing generic manufacturers to exploit the underlying chemistry.
-
Subsequent patents in this domain focus on advanced derivatives, formulations, and targeted delivery, which could present freedom-to-operate barriers.
-
The patent landscape emphasizes continuous innovation in heterocyclic compounds for pharmaceutical applications.
-
Companies should undertake detailed freedom-to-operate assessments when developing compounds similar to those claimed to avoid infringement.
FAQs
1. Are the claims of U.S. Patent 4,626,531 still enforceable?
No. The patent expired in December 2003, rendering its claims unenforceable. It is now part of the public domain.
2. Can I develop products based on the chemistry disclosed in this patent?
Yes. Since the patent has expired, the chemical space is free for research, development, and commercialization, provided no newer patents cover specific derivatives or methods.
3. Are there modern patents protecting derivatives of 3-hydroxypyridine?
Yes. Recent patents focus on derivatives with improved pharmacokinetics, formulations, or specific therapeutic indications. A patent landscape search is necessary for detailed freedom-to-operate analysis.
4. What kind of medical conditions are associated with compounds similar to those claimed in the patent?
Primarily anti-inflammatory, analgesic conditions such as arthritis, rheumatoid disease, and pain management.
5. How does this patent compare to other heterocyclic patent families?
It is an example of early innovation in pyridine-based pharmacophores, which later evolved into more specific or targeted compounds protected by subsequent patent filings.
References
- U.S. Patent and Trademark Office. (1986). US 4,626,531.
- European Patent Office. (2021). Patent classification data.
- Lira, V., & Roberts, D. (2014). Landscape analysis of pyridine derivatives in pharma. J. Chem. Inf. Model., 54(8), 2489-2501.
More… ↓
⤷ Start Trial
|
